EGFR and non-small cell lung carcinoma: In the present case, a patient with EGFR-mutated NSCLC who developed resistance to third-generation TKIs and subsequent disease progression despite chemotherapy and antiangiogenic therapy achieved marked regression of pulmonary target lesions with ivonescimab monotherapy, accompanied by minimal treatment-related toxicity.